Anatara Lifesciences (ASX:ANR) is pleased to announce the successful completion of its pivotal Target Animal Safety (TAS) Study for DetachTM, the Company's lead product for the control of diarrhoea in piglets.
Anatara Lifesciences Ltd (ASX:ANR) today released its Appendix 4E for the period ending 30th June 2016.
MMJ PhytoTech Limited (ASX:MMJ) is pleased to advise that its wholly-owned, Israeli-based subsidiary PhytoTech Therapeutics Limited ("PTL"), will commence a Phase 2 clinical study into the efficacy of the its PTL101 capsules in treating intractable epilepsy in children.
MMJ PhytoTech Limited (ASX:MMJ) ("MMJ" or "the Company") is pleased to advise that Catherine Harvey has been appointed as Chief Operations Officer, effective 1 September 2016.
MMJ PhytoTech Limited (ASX:MMJ) is pleased to advise that its wholly-owned subsidiary United Greeneries has executed a binding letter of intent with Cowichan Tribes in respect to the leasing of a 13-acre strategic land package located immediately adjacent to the Company's existing Duncan Facility.
Chairman & CEO, Dr Mel Bridges said, "We are extremely pleased to report a positive cash flow for the last quarter, reinforcing a strong balance sheet and cash position. Our cash position allows Anatara the flexibility to execute on moving both our animal and human applications forward to commercial launch," Dr Bridges added.
MMJ PhytoTech Ltd (ASX:MMJ) are pleased to provide the Company's latest Investor Presentation for July 2016, 'From Farm to Pharma'.
